Tavneos

Obtain LFTs prior to initiation, every 4 weeks during the 1^st 6 months, then as clinically indicated. Evaluate and consider interrupting therapy if ALT/AST elevated to >3×ULN. Discontinue if ALT/AST >5×ULN, or transaminases >3×ULN with elevated bilirubin >2×ULN until Tavneos-induced liver injury is ruled out. Discontinue immediately if angioedema occurs; treat appropriately. Screen for HBV infection by measuring HBsAg and anti-HBc prior to initiation. Monitor those with evidence of HBV infection for signs of hepatitis or HBV reactivation during and for 6 months following Tavneos. If HBV reactivation occurs, immediately discontinue Tavneos and any concomitant HBV reactivation-associated therapy. Avoid in those with active, serious infection. Consider risks/benefits prior to initiation: with chronic or recurrent infection, or history of serious or opportunistic infections, exposure to TB, travel to, or residence in, areas with endemic TB or mycoses, conditions that predispose to infection. Monitor closely for infection during and after therapy; interrupt if serious or opportunistic infection develops. Active, untreated and/or uncontrolled chronic liver disease (eg, chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis), cirrhosis, or severe hepatic impairment (Child-Pugh Class C): not recommended; consider risk/benefit prior to therapy. Dialysis. Pregnancy. Nursing Mothers.